Previous 10 | Next 10 |
2023-11-01 04:17:37 ET More on United Therapeutics United Therapeutics Shifts Focus To Tyvaso DPI Amid Generic Threat United Therapeutics: Fundamental, Technical Analyses Justify A Buy Decision United Therapeutics Q3 2023 Earnings Preview United Therapeutics ...
2023-10-31 12:39:29 ET More on United Therapeutics United Therapeutics Shifts Focus To Tyvaso DPI Amidst Generic Threat United Therapeutics: Both Fundamental And Technical Analyses Justify A Buy Decision United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth M...
Up to 60,000 patients in the United States may have PPF, with only one approved therapy available United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the first patient has enrolled in the registration-phase TETON PPF study, whi...
United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Patrick Poisson , Executive Vice President, Technical Operations, will provide an overview and update on the company’s business during a fireside chat session at the UBS Biopharma Co...
2023-10-31 02:17:12 ET Summary I will recap the eleven partnership deals MannKind has been involved in over its operation as a corporation. I will share my opinion as it relates to the current status of these eleven partnerships. I will discuss why it is my opinion that MannKi...
2023-10-30 06:33:26 ET More on United Therapeutics United Therapeutics Shifts Focus To Tyvaso DPI Amidst Generic Threat United Therapeutics: Both Fundamental And Technical Analyses Justify A Buy Decision United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth M...
United Therapeutics Corporation (Nasdaq: UTHR ) and Miromatrix Medical Inc. (Nasdaq: MIRO ) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company focused on the development of bioengineered organs composed of human ...
United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its third quarter 2023 financial results before the market opens on Wednesday, November 1, 2023. United Therapeutics will host a public webcast Wednesday, November 1, 2023, at 9:00 a.m. Eastern Time. The ...
2023-10-23 03:35:36 ET Summary United Therapeutics' strategic pivot to Tyvaso DPI aims to thwart generic competition through enhanced efficacy and patient compliance. Robust liquidity and operational cash flow; low likelihood of external financing required in the near term. In...
2023-10-22 12:25:39 ET Summary United Therapeutics Corporation is in a long-term uptrend, reaching a new all-time high, indicating strong demand for the stock. The company has a competitive advantage with a diverse and unique product portfolio, driving revenue and profit growth. ...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...